Clinical Overview of MDM2/X-Targeted Therapies
نویسندگان
چکیده
منابع مشابه
Clinical Overview of MDM2/X-Targeted Therapies
MDM2 and MDMX are the primary negative regulators of p53, which under normal conditions maintain low intracellular levels of p53 by targeting it to the proteasome for rapid degradation and inhibiting its transcriptional activity. Both MDM2 and MDMX function as powerful oncogenes and are commonly over-expressed in some cancers, including sarcoma (~20%) and breast cancer (~15%). In contrast to tu...
متن کاملProgress in Targeted Therapies for Cancer: Overview
Targeted therapies for cancer can be broadly defined as treatments directed against abnormally activated molecules or physiological processes required for maintenance or progression of tumours. In recent years, many targeted therapies have become established in daily clinical practice and a huge number of agents are in various stages of pre-clinical and clinical development. The concept of targ...
متن کاملClinical Significance of Skin Toxicity due to EGFR-Targeted Therapies
Many small molecules and monoclonal antibodies blocking the activity of Epidermal Growth factor receptor (EGFR) have been developed and have shown clinical activity in patients with non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer (CRC), and are in clinical development for a range of other solid tumors. The toxicity profile of such agents is characterized by a typica...
متن کاملClinical Advancements in the Targeted Therapies against Liver Fibrosis
Hepatic fibrosis, characterized by excessive accumulation of extracellular matrix (ECM) proteins leading to liver dysfunction, is a growing cause of mortality worldwide. Hepatocellular damage owing to liver injury leads to the release of profibrotic factors from infiltrating inflammatory cells that results in the activation of hepatic stellate cells (HSCs). Upon activation, HSCs undergo charact...
متن کاملA national cancer clinical trials system for targeted therapies.
Today, modern technologies in genomics, biomarker detection, and molecular imaging are providing information that will enable physicians to select appropriate treatments for individual cancer patients from among more than 800 new experimental drugs and antibodies that target the products of the aberrant genes that can cause cancer. At this promising time in cancer research, the U.S. National Ca...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Oncology
سال: 2016
ISSN: 2234-943X
DOI: 10.3389/fonc.2016.00007